New Jersey is currently home to 1661 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Leveraging the Emergency Department (LEAD) Study
NCT06605534
Recruiting
This is a pilot Type 1 Hybrid Effectiveness-Implementation Trial. The study will first examine reach in a non-traditional setting (the Emergency Department - ED) that uses an Electronic Health Record (EHR)-embedded Social Determinants of Health (SDoH) screening tool to identify lung screening-eligible patients for a tailored intervention to increase lung screening uptake. Reach is defined as the absolute number, proportion, and representativeness of individuals targeted for lung screening knowle... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/07/2025
Locations: Ocean Medical Center, Brick, New Jersey
Conditions: Lung Cancer
Register for Updates
Assessing Social Determinants of Health to Increase Cancer Screening
NCT06052449
Recruiting
A multilevel lung screening intervention that pairs Social Determinants of Health (SDoH) screening and referral with a tailored health communication and decision support tool for lung screening has the potential to significantly impact lung screening uptake among at-risk individuals in the community, particularly among those who face barriers related to SDoH. In addition, findings will advance the understanding of effective strategies for improving lung screening and prevention efforts in non-tr... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/07/2025
Locations: Hackensack Meridian Health - Center for Discovery and Innovation, Nutley, New Jersey
Conditions: Lung Cancer
Register for Updates
The INSPIRE-Lung Study
NCT05824273
Recruiting
LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals nationwide.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/07/2025
Locations: Hackensack Meridian Health - Center for Discovery and Innovation, Nutley, New Jersey
Conditions: Lung Cancer
Register for Updates
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
NCT04872543
Recruiting
The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows decitabine to work better than decitabine given alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Malignant Peripheral Nerve Sheath Tumors (MPNST)
Register for Updates
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
NCT02119702
Recruiting
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection (YAPHIV) as they transition into adulthood. A group of of perinatally exposed but uninfected young adults from a similar sociodemographic background and age distribution will be enrolled for comparison.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: Rutgers - New Jersey Medical School, Newark, New Jersey
Conditions: HIV/AIDS
Register for Updates
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
NCT01310023
Recruiting
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
Gender:
ALL
Ages:
All
Trial Updated:
01/07/2025
Locations: Rutgers - New Jersey Medical School, Newark, New Jersey
Conditions: Antiretroviral Toxicity
Register for Updates
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
NCT06594991
Recruiting
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
Conditions: Advanced Melanoma
Register for Updates
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
NCT03506308
Recruiting
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Arteriovenous Fistula
Register for Updates
A Study of a Weight Loss Intervention in People With Endometrial Cancer
NCT06751589
Recruiting
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Endometrial Cancer
Register for Updates
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT04895709
Recruiting
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Register for Updates
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
NCT05079698
Recruiting
The researchers are doing this study to find out whether giving 177Lu-PSMA-617 followed by a type of radiation therapy called SBRT (stereotactic body radiation therapy) is a safe treatment for your cancer. The study agent has been shown to target tumor cells, and the researchers think that adding 177Lu-PSMA-617 to SBRT may prevent or delay the cancer from continuing to spread.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Prostate Cancer
Register for Updates
Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
NCT04900818
Recruiting
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Register for Updates